



Cholangiocarcinoma Foundation®

2025 Cholangiocarcinoma Foundation Research Fellowship

The Cholangiocarcinoma Foundation (CCF) is a nonprofit organization founded in 2006 to find a cure and advance scientific and medical research related to the diagnosis, treatment, and cure of cholangiocarcinoma (bile duct cancer) to improve the quality of life for those affected by cholangiocarcinoma.

CHOLANGIOCARCINOMA FOUNDATION RESEARCH FELLOWSHIP PROGRAM

In 2015, the Foundation established a Research Fellowship Program to support early-career, high-quality, innovative researchers worldwide focusing on studying cholangiocarcinoma. The intent is to help them better understand this complex disease and accelerate the pace of finding a cure. To date, the Foundation has invested more than \$3.01 million in seed funding for basic, translational, and clinical research to 60 awardees at 34 institutions from 6 countries. The Foundation chooses grant recipients carefully to ensure they will build working relationships between researchers, institutions, and industry and share information, samples, and expertise with others in the field. Prior experience in the field of cholangiocarcinoma is not required.

SUBMIT LETTERS OF INTENT

KEY DATES:

Letter of Intent Deadline:

Wednesday, September 11, 2024, 11:59 pm (US Eastern)

Applicants Notified of Decision Status of Letter of Intent:

Friday, November 08, 2024

Full Application Deadline:

(for those invited to apply based on the Letter of Intent)

Friday, December 27, 2024, 11:59 pm (US Eastern)

FUNDING:

- One year of grant support up to \$65,000
- Funding for expenses related to the research project, which may include the salary and benefits of the grant recipient, may be used
- Must include travel budget for oral presentations at the 2026 CCF Annual Conference in Salt Lake City, UT.
- *CCF will not fund indirect costs or institutional overhead*

AWARD PERIOD

- June 01, 2025 - May 31, 2026, for a 1-year grant

RESEARCH FOCUS:

- **Basic Science:** Research using laboratory-based models without clinical data from patients
- **Translational Science:** Research studying human samples or data obtained from human samples, annotated with clinical outcome data
- **Clinical Science:** Studies of outcomes in human patients; including population and epidemiology research

TOPIC OF INTEREST

CCF gives priority to funding impactful cholangiocarcinoma-associated projects related to:

- Early detection and prevention approaches, including PSC, IBD, and hepatitis-related CCA
- Radiomics and radiogenomics
- Drug discovery using various types of model systems
- Improvements in immuno-therapy for CCA
- Correlative studies related to clinical trial data or samples
- Real-world data research focused on population health and quality-related measures and outcomes

LETTER OF INTENT NARRATIVE

- Research that can impact cholangiocarcinoma patient outcomes
- Hypothesis-driven specific aims with well-designed analyses
- A feasible project completed within the period of the grant
- An identified mentor who will be able to support the project aims and the applicant
- Statistical rigor

EVALUATION OF LETTERS OF INTENT

- The Letters of Intent (LOI) will be reviewed by the CCF Scientific Review Committee, comprised of established clinical, translational, and basic science researchers, as well as patient advocates. Applicants whose LOI is deemed most worthy are invited to submit complete applications.

KEY COMPONENTS OF A LETTER OF INTENT SUBMISSION

- The LOI should provide a summary of the proposed research project, specific aims and rationale, scientific approach, significance, and innovation (One-page limit)
- References (One-page limit)
- Applicant NIH Biosketch (preferred) or CV (up to five-pages)
- Mentor NIH Biosketch (preferred) or CV (up to five-pages)
- Prior awardee only should also provide a progress report and a statement of how the second year of CCF funding would lead to additional support from NIH or other sustained funding (One-page limit)

ELIGIBILITY:

DEGREE

- Doctor of Medicine
- Doctor of Philosophy
- Doctor of Pharmacy
- Doctor of Veterinary Medicine

ACADEMIC LEVEL

- Postdoctoral Fellows and Clinical Fellows who do not have faculty positions.
- Junior Faculty **within first three years of appointment at the time of application**; includes Instructors and Assistant Professors.

INSTITUTIONAL REQUIREMENTS

- Academic or medical, or research institutions based anywhere worldwide
- Sponsoring institution must assign a Mentor in the proposed research field who assumes responsibility and provides guidance for the research

OTHER ELIGIBILITY REQUIREMENTS

- Prior experience in the field of cholangiocarcinoma is not required
- Current 2024 fellowship recipients are eligible to apply to continue their current project (progress report of current project must be submitted)
- There are no restrictions for applicants regarding age, gender, race, disability, or national origin/residence

=====

Link to 2025 submission portal –

<< <https://proposalcentral.com/> >>

For first-time users, please register for an [ORCID iD](#), then create an account on Proposal Central.


FAQs:

How to find the Grant Opportunity?


When you log in to ProposalCentral, navigate to the Grants opportunity tab on the Home page.



In the Search box, search Cholangiocarcinoma Foundation and click the Apply Now button to Initiate a Proposal.



You can also find the Opportunity by scrolling through the list in the Filter by Grant Maker dropdown.



How many Research Fellowships do you award each year?

The number of grants in each funding cycle is determined based on the availability of funds.

Can multiple applications from the same institution apply for this award?

Yes

Are PIs working in non-US-based institutions eligible for this award?

Yes

How do the criteria for prior awardees differ from those for first-time applicants?

Prior awardees who can demonstrate that additional support is highly likely to lead to further long-term funding will be prioritized.


Can I have an extension on the due date?

No, the LOI must be received before the deadline of 11:59pm (US Eastern) on Wednesday, September 11, 2024.


How to Access My Saved LOI?

You can access your Saved LOI


- By clicking on the Identifier number from the Home tab



- You can also access it via the Proposal tab by clicking on Edit next to the Identifier number.



- To delete duplicate Proposals, click the Delete button in the Proposals tab.



Who do I contact if I have questions?

- If you have problems with the platform, please contact ProposalCentral:
 - by phone (toll-free): 800 875 2562 (Toll-free U.S. and Canada)
 - by or +1 703 964 5840 (Direct Dial International)
 - by email: pcsupport@altum.com

- If you have specific questions about the LOI or the program offered by Cholangiocarcinoma Foundation or its guidelines, please contact the CCF Grants manager: Research@cholangiocarcinoma.org